TITLE

Letrozole improved disease-free survival in patients with breast cancer

PUB. DATE
April 2008
SOURCE
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p33
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the improved treatment results of Letrozole. A research showed that patients with breast cancer experienced disease-free survival after being treated with Letrozole and even with the discontinuation of adjuvant tamoxifen therapy. The study which compared Letrozole results with placebo also found out that women on Letrozole reported diagnoses of fractures and osteoporosis
ACCESSION #
31705869

 

Related Articles

  • VALERIE / july 2009.  // O, The Oprah Magazine;Oct2011, Vol. 12 Issue 10, p203 

    The article focuses on a woman breast cancer patient who underwent chemotherapy and mastectomy. She took a course of tamoxifen, an oral medication that could reduce recurrence of cancer by up to 50 percent, but that came with its own set of side effects. The patient also underwent double...

  • Prolonging Tamoxifen Therapy for Primary Breast Cancer. Fisher, Bernard; Brown, Ann; Wolmark, Norman; Redmond, Carol; Wickerham, D. Lawrence; Wittliff, James; Dimitrov, Nikolay; Legault-Poisson, Sandra; Schipper, Harvey; Prager, David // Annals of Internal Medicine;May87, Vol. 106 Issue 5, p649 

    Discusses a study that determined whether prolonging the duration of tamoxifen administration beyond the cessation of a combined chemotherapy regimen benefits patients with primary breast cancer. Information on the nonsteroidal compound tamoxifen; Effect of an additional year of tamoxifen on...

  • Letrozole. Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 12, p1681 

    Letrozole (Femara®) is a third-generation, nonsteroidal aromatase inhibitor. Adjuvant therapy with letrozole is more effective than tamoxifen in postmenopausal women with hormone-responsive early breast cancer, and extended adjuvant therapy with letrozole after the completion of adjuvant...

  • Miscellaneous.  // Annals of Oncology;May2012 Supplement 2, Vol. 23 Issue suppl_2, pii46 

    No abstract available.

  • Benefits of tamoxifen for breast cancer prevention do not always outweigh overall risks. Strickland, Carmen // Journal of Family Practice;Dec2002, Vol. 51 Issue 12, p1016 

    The article discusses research being done on the benefits of tamoxifen therapy for breast cancer patients and the significant adverse outcomes associated with such treatment. It references a study by researchers at the International Breast Cancer Intervention Study published in the 2002 issue of...

  • Experts regret early cessation of anticancer drug trial. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);10/18/2003, Vol. 327 Issue 7420, p885 

    Reports on the discontinuation of an anticancer drug study on breast cancer patients who had already undergone tamoxifen therapy. Reasons for the discontinuation, including the similarities between the group taking the drug and the group taking the placebo; Description of the drug used in the...

  • 900 mg daily of gabapentin was effective for hot flashes in women with breast cancer.  // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p41 

    This article presents a study which states that 900 mg daily of gabapentin was effective for hot flashes in women with breast cancer. In the study, 420 women 18 years of age with breast cancer who were having an average 2 hot flashes daily. 71% of women were taking tamoxifen. Women receiving...

  • Tamoxifen/paroxetine/citalopram interaction.  // Reactions Weekly;10/22/2011, Issue 1374, p33 

    The article describes the case of a 47-year-old woman with breast cancer who developed hot flashes and a major depressive episode after receiving tamoxifen given before a surgery.

  • Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial. Rizzo, Toni // MD Conference Express;Feb2013, p16 

    The article discusses chemotherapy that prolongs the survival of isolated local or regional recurrence (ILRR) of breast cancer. It notes that patients who developed ILRR have high risk of distant metastasis and death and the randomized trial of adjuvant chemotherapy for patients treated with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics